OncoGenex Pharmaceuticals Inc. Doubles Down on Prostate Cancer, as Competition Heats Up
Published: Mar 12, 2012
March 09, 2012 -- There’s some aggressive jockeying going on in the prostate cancer market, and today Vancouver, BC and Bothell, WA-based OncoGenex Pharmaceuticals made some moves that it hopes will keep its lead horse in the race. OncoGenex (NASDAQ: OGXI) and its partner Teva Pharmaceutical said today they are expanding one pivotal-stage clinical trial for men with prostate cancer, dropping another, and starting a newly designed trial that will seek to differentiate its experimental drug called custirsen. The new trial, of 630 men, will look to see whether getting their second round of chemotherapy can live longer on a combo of custirsen and Sanofi’s cabazitaxel (Jevtana).